AAPS PharmSciTechHumansNanoparticlesSolubilityPyrazinesBenzamides
Fabrication of Second-Generation Acalabrutinib Nanocrystals by Employing the Nano-Edge Method for Improving the Physico-Chemical Properties and Forecasting their In-Silico Pharmacokinetic Behaviour.
Bharath M, Ujala Gupta, Anish Dhuri, Tanmoy Kanp, Khushi Rode, Sharon Munagalasetty, Vasundhra Bhandari, Soumyadip Mukherjee, Arvind Gulbake, Pankaj Kumar Singh
Published: 202610.1208/s12249-025-03298-y
Abstract
Acalabrutinib (ACL) is approved by the USFDA and classified as a BCS class II drug, primarily used for treating chronic lymphocytic leukaemia. It is characterised by low solubility, particularly at higher pH levels, which results in reduced systemic…
Preview only. Read the full abstract at the source